Effect of repetitive transcranial magnetic stimulation combined with Butylphthalide Soft Capsules in the treatment of Parkinson′s disease with cognitive impairment
HU Xiaoying LEI Hongyan MA Shanshan ZHANG Wei ZHANG Tong WANG Ruiping
Department of Neurology,Liaoning Jinqiu Hospital,Liaoning Province,Shenyang 110000,China
Objective To explore the effect of repetitive transcranial magnetic stimulation combined with Butylphthalide Soft Capsules in the treatment of Parkinson's disease with cognitive impairment.Methods A total of 100 patients with Parkinson's disease combined with cognitive dysfunction admitted to Liaoning Jinqiu Hospital from July 2019 to August 2022 were selected and divided into study group(50 cases)and control group(50 cases)according to random number table method.The control group was treated with Butylphthalide Soft Capsules,and the study group was treated with repetitive transcranial magnetic stimulation on the basis of the control group.The clinical efficacy of the two groups was compared.Results After treatment,the Montreal cognitive assessment (MoCA)and Brathel index (BI)scores of the study group were higher than those of the control group,and the National Institutes of Health stroke scales(NIHSS)and modified Rankin scale(MRS) scores were lower than those of the control group,with statistically significant differences (P<0.05).Conclusion Repetitive transcranial magnetic stimulation combined with Butylphthalide Soft Capsules has a good effect on the early rehabilitation of patients with Parkinson's disease complicated with cognitive dysfunction,which can significantly promote the recovery of nervous system and cognitive function,and improve clinical symptoms and prognosis.It has good clinical application value.
胡晓颖;雷鸿雁;马珊珊;张 薇;张 彤;王瑞萍. 重复经颅磁刺激配合丁苯酞软胶囊治疗帕金森合并认知功能障碍患者的效果[J]. 中国当代医药, 2023, 30(20): 46-49.
HU Xiaoying LEI Hongyan MA Shanshan ZHANG Wei ZHANG Tong WANG Ruiping. Effect of repetitive transcranial magnetic stimulation combined with Butylphthalide Soft Capsules in the treatment of Parkinson′s disease with cognitive impairment. 中国当代医药, 2023, 30(20): 46-49.